Systematic review shows adalimumab with MTX reduces relapse risk in pediatric JIA-U, indicating a preferred treatment approach.
Initiating adalimumab on MTX, and maintaining therapy once remission is achieved, markedly lowers relapse risk and supports steroid-sparing while preserving vision in pediatric JIA-U. These findings endorse adalimumab with MTX as the preferred strategy across initiation and continuation scenarios.
No takes yet. Share an insight, caveat, or question.
Alshehri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: